Citigroup Has Lowered Expectations for Zimmer Biomet (NYSE:ZBH) Stock Price

Key Points

• Citigroup lowered its price target on Zimmer Biomet from $95 to $93 while keeping a neutral rating, implying about 12% upside from the stock’s prior close.
• Analyst sentiment is mixed but mostly cautious, with the broader consensus rating at Hold and an average price target of $102.70, though several firms have recently trimmed their targets or maintained neutral/hold views.
• Zimmer Biomet beat quarterly expectations, reporting EPS of $2.09 versus $1.86 expected and revenue of $2.09 billion, while also guiding FY2026 EPS to $8.40-$8.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price objective reduced by analysts at Citigroup from $95.00 to $93.00 in a report issued on Thursday,Benzinga reports. The firm presently has a "neutral" rating on the medical equipment provider's stock. Citigroup's price objective points to a potential upside of 12.16% from the company's previous close.

Several other research firms have also recently commented on ZBH. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. Leerink Partners began coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They set a "hold" rating and a $101.00 price target on the stock. Barclays cut their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an "underweight" rating on the stock in a report on Wednesday, April 29th. Finally, BTIG Research restated a "neutral" rating on shares of Zimmer Biomet in a report on Monday, March 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $102.70.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded up $0.36 during trading hours on Thursday, hitting $82.92. 1,712,451 shares of the stock were exchanged, compared to its average volume of 2,289,263. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The stock has a market capitalization of $16.04 billion, a P/E ratio of 21.54, a P/E/G ratio of 1.95 and a beta of 0.48. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $108.29. The business's 50-day moving average is $88.28 and its two-hundred day moving average is $90.73.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. The firm had revenue of $2.09 billion for the quarter, compared to analysts' expectations of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company's quarterly revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts expect that Zimmer Biomet will post 8.47 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.28% of the company's stock.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds have recently bought and sold shares of the company. Glenmede Trust Co. NA raised its holdings in Zimmer Biomet by 14.2% in the first quarter. Glenmede Trust Co. NA now owns 10,160 shares of the medical equipment provider's stock worth $919,000 after purchasing an additional 1,261 shares during the period. Bank of America Corp DE raised its holdings in Zimmer Biomet by 19.2% in the first quarter. Bank of America Corp DE now owns 1,549,790 shares of the medical equipment provider's stock worth $140,132,000 after purchasing an additional 249,175 shares during the period. Hamilton Wealth LLC acquired a new stake in Zimmer Biomet in the first quarter worth $678,000. Edgestream Partners L.P. raised its holdings in Zimmer Biomet by 365.3% in the first quarter. Edgestream Partners L.P. now owns 13,469 shares of the medical equipment provider's stock worth $1,218,000 after purchasing an additional 10,574 shares during the period. Finally, Kentucky Retirement Systems raised its holdings in Zimmer Biomet by 13.5% in the first quarter. Kentucky Retirement Systems now owns 14,116 shares of the medical equipment provider's stock worth $1,315,000 after purchasing an additional 1,683 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.